On the Prevalence of Autoimmune Disease Markers in a Working Population and its Relationship to Wellness

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Umber Waheed ◽  
Roger Greenlaw ◽  
Sherry Falsetti
Keyword(s):  
Autoimmune Disease ◽  
Clinical Markers ◽  
Working Population ◽  
Early Disease ◽  
Therapeutic Lifestyle Change ◽  
Serial Testing ◽  
Healthy Working ◽  
Clinically Significant ◽  
Healthier Living ◽  
Asymptomatic Individuals

Background: Autoimmune disease prevalence is rising at an increasing rate. However, little research currently exists on pre-screenings for autoimmunity and early disease management. We propose wellness visits should include an autoimmune disease panel screening for autoantibodies at preclinical and clinical levels. Methods: A working population of individuals without formally diagnosed autoimmune disease underwent company-sponsored wellness visits. Wellness markers such as blood pressure and lipid measurements and an autoantibody panel were obtained during the visits. Participants were offered functional medicine information afterwards. Results: Seventy-eight participants completed the visits. One or more wellness marker “abnormalities” were seen in 97% (76/78) of participants. Each wellness marker’s frequency of abnormality ranged from 13–82% of the participants. Preclinical or clinical autoantibody levels were seen in 53% (41/78) of the “healthy” working population with no previous autoimmune disease diagnoses. Preclinical markers were seen in 21% (16/78)of participants and clinical markers were seen in 32% (25/78) of participants. At least one wellness screening abnormality was seen in 98% (40/41) of participants with positive autoantibody findings. At least 50% of participants with a specific wellness abnormality tested at the higher “clinically” significant autoantibody levels. Conclusion: Preliminary findings from this study suggest that the integration of an autoantibody panel in wellness visits may be beneficial. Individuals may also consider healthier living practices and proactive prevention of autoimmune disease pathogenesis through applications of functional medicine and therapeutic lifestyle change. Clinical marker findings in asymptomatic individuals raises a limitation in the usefulness of such a panel, and further research such as a placebo-controlled prospective cohort study with an intervention trial or serial testing of autoantibody prevalence is needed.

Differential relations of somatic complaints in a young, healthy working population

2004 ◽  
Author(s):  
E. Persijn ◽  
G. Crombez ◽  
A. van Nieuwenhuyse ◽  
O. Vandenbergh ◽  
G. Moens
Keyword(s):  
Somatic Complaints ◽  
Working Population ◽  
Healthy Working ◽  
Differential Relations

Incidence and prediction of checkpoint inhibitor immune-related nephrotoxicity.

2020 ◽  
Vol 38 (5_suppl) ◽  
pp. 91-91
Author(s):  
Jonathan D Sorah ◽  
Tracy L. Rose ◽  
Roshni Radhakrishna ◽  
Vimal Derebail ◽  
Matthew I. Milowsky
Keyword(s):  
Autoimmune Disease ◽  
Adverse Events ◽  
Checkpoint Inhibitors ◽  
Kidney Injury ◽  
Retrospective Chart Review ◽  
Tumor Type ◽  
True Incidence ◽  
Platinum Based Chemotherapy ◽  
Increased Risk ◽  
Clinically Significant

91 Background: Immune checkpoint inhibitors (ICIs), through inhibition of self-tolerance, have the potential to cause immune-related adverse events that can affect any organ, including the kidneys. Our study aimed to better characterize the incidence of and predictive characteristics for immune-related nephrotoxicity. Methods: All patients at the University of North Carolina (UNC) who received ICIs between April 2014 and December 2018 for any malignancy were identified. Patients on dialysis or those who received concurrent platinum-based chemotherapy were excluded. Any patient who subsequently had a clinically significant acute kidney injury (AKI), defined as a doubling or more of baseline creatinine, was included for analysis. A retrospective chart review was performed to determine the cause of AKI. Any uncertain cases were reviewed by two nephrologists for expert consensus (R.R. and V.D.). Results: 1766 patients received an ICI during the study period. 123 (7%) patients had AKI within one year of the first ICI dose. 14 were due to immune-related nephrotoxicity (11% of patients with AKI and 0.8% of all ICI patients). Pre-existing autoimmune disease was more likely in patients with immune-related nephrotoxicity than in those with non-immune AKI (14% vs 3%, p = 0.04). Similarly, concurrent or prior other immune-related adverse events were more common in patients with immune-related AKI (57% vs 6%, p = 0.01). Patients with immune-related AKI were more likely to see a nephrologist (57% vs 23%, p = 0.007) and had a more profound increase in creatinine from baseline (median 2.6 vs 1.6, p = 0.02). Age, sex, urinalysis findings, and primary tumor type were not associated with increased risk. Conclusions: The true incidence of ICI related nephrotoxicity is difficult to ascertain due to the many confounders that contribute to AKI in this population. Severe immune-related nephrotoxicity is rare, but patients with preexisting autoimmune disease or history of immune-related adverse events are at increased risk.

Comparison of spinal sagittal parameters by time of day in a healthy working population: Do we bend during the day?

2018 ◽  
Vol 31 (2) ◽  
pp. 381-388 ◽  
Author(s):  
Okan Ozkunt ◽  
Kerim Sariyilmaz ◽  
Halil Can Gemalmaz ◽  
Ozcan Kaya ◽  
Fatih Dikici
Keyword(s):  
Time Of Day ◽  
Working Population ◽  
Healthy Working ◽  
Sagittal Parameters

scholarly journals Clinical Conditions and Their Impact on Utility of Genetic Scores for Prediction of Acute Coronary Syndrome

2021 ◽  
Author(s):  
Jiwoo Lee ◽  
Tuomo Kiiskinen ◽  
Nina Mars ◽  
Sakari Jukarainen ◽  
Erik Ingelsson ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
P Value ◽  
Coronary Syndrome ◽  
Polygenic Scores ◽  
Hernia Inguinal ◽  
Clinically Significant ◽  
Asymptomatic Individuals ◽  
The Uk ◽  
Clinical Conditions ◽  
Incident Cases

Background - Acute coronary syndrome (ACS) is a clinically significant presentation of coronary heart disease (CHD). Genetic information has been proposed to improve prediction beyond well-established clinical risk factors. While polygenic scores (PS) can capture an individual's genetic risk for ACS, its prediction performance may vary in the context of diverse correlated clinical conditions. Here, we aimed to test whether clinical conditions impact the association between PS and ACS. Methods - We explored the association between 405 clinical conditions diagnosed before baseline and 9,080 incident cases of ACS in 387,832 individuals from the UK Biobank. Results were replicated in 6,430 incident cases of ACS in 177,876 individuals from FinnGen. Results - We identified 80 conventional (e.g., stable angina pectoris (SAP), type 2 diabetes mellitus) and unconventional (e.g., diaphragmatic hernia, inguinal hernia) associations with ACS. The association between PS and ACS was consistent in individuals with and without most clinical conditions. However, a diagnosis of SAP yielded a differential association between PS and ACS. PS was associated with a significantly reduced (interaction p-value=2.87×10-8) risk for ACS in individuals with SAP (HR=1.163 [95% CI: 1.082-1.251]) compared to individuals without SAP (HR=1.531 [95% CI: 1.497-1.565]). These findings were replicated in FinnGen (interaction p-value=1.38×10-6). Conclusions - In summary, while most clinical conditions did not impact utility of PS for prediction of ACS, we found that PS was substantially less predictive of ACS in individuals with prevalent stable CHD. PS may be more appropriate for prediction of ACS in asymptomatic individuals than symptomatic individuals with clinical suspicion for CHD.

scholarly journals Predictors for Outcomes related to upper Extremity Musculoskeletal Disorders in a healthy Working Population: a methodological Approach

2020 ◽  
Author(s):  
Oliver Lotter ◽  
Tobias Lieb ◽  
Jochen Molsner ◽  
Viktor Breul
Keyword(s):  
Upper Extremity ◽  
Musculoskeletal Disorders ◽  
Methodological Approach ◽  
Dash Score ◽  
Working Population ◽  
Primary Analysis ◽  
Cross Sectional ◽  
Clinical Endpoints ◽  
Work Related ◽  
Healthy Working

Abstract BackgroundTo investigate the association between different clinical endpoints and the presence of upper extremity work-related musculoskeletal disorders (WMSDs) in a healthy working population. Furthermore, the influence of socio-demographic, work-related and individual predictors on different endpoints was examined.MethodsTwo self-completion questionnaires were administered to 70 workers and employees. In addition, a standardized physical examination and an industry test were performed in this cross-sectional study. Correlations between WMSDs and clinical endpoints were analysed with the Spearman method. Depending on the type of dependent endpoint, linear or logistic multivariate regression models were used to study the strength of associations with a pre-defined set of potential influencing factors.ResultsThe prevalence of WMSDs was 56% (39/70). Correlations between WMSDs and the DASH score / pain under strain (VAS) were by far the strongest ones. Independent predictors could not be identified as risk factors for WMSDs, but there was some correlation between these factors.ConclusionsThe DASH score, used in the primary analysis of the study data, remains a close candidate for best surrogate endpoint for WMSD detection. The VAS has to be examined for this role in further research. Our analysis should help to improve the methodological quality of future occupational health studies through improved standards.Trial registrationThis study was registered at ClinicalTrials.org with the identifier NCT03014128, on January 9, 2017.

Clinical markers of early disease in persons near onset of Huntington's disease

Neurology ◽  
2001 ◽  
Vol 57 (4) ◽  
pp. 658-662 ◽  
Author(s):  
J. S. Paulsen ◽  
H. Zhao ◽  
J. C. Stout ◽  
R. R. Brinkman ◽  
M. Guttman ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Clinical Markers ◽  
Early Disease

scholarly journals Prevalence of viral hepatitis (B and C) serological markers in healthy working population

2013 ◽  
Vol 105 (5) ◽  
pp. 249-254 ◽  
Author(s):  
José Luis Calleja-Panero ◽  
Elba Llop-Herrera ◽  
Montserrat Ruiz-Moraga ◽  
Juan de la Revilla-Negro ◽  
Eva Calvo-Bonacho ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Serological Markers ◽  
Working Population ◽  
Healthy Working ◽  
Viral Hepatitis B

scholarly journals O049 Sleep quality and its impact on children with primary ciliary dyskinesia

2021 ◽  
Vol 2 (Supplement_1) ◽  
pp. A21-A21
Author(s):  
I Ewert ◽  
P Robinson ◽  
A Adams ◽  
M Vandeleur
Keyword(s):  
Sleep Quality ◽  
Sleep Disturbance ◽  
Screening Program ◽  
Lung Mechanics ◽  
Poor Sleep ◽  
Clinical Markers ◽  
Subjective Sleep Quality ◽  
Obstructive Sleep ◽  
Clinically Significant ◽  
The Impact

Abstract Background PCD is a rare, progressive disease resulting in upper respiratory manifestations and abnormal lung mechanics that increase one’s risk of obstructive sleep apnoea. This study aims to characterise the sleep quality of children with PCD and its impacts on mood and HRQOL. Methods Children with PCD aged 0–19 years with stable respiratory symptoms were recruited. Subjective sleep quality was assessed by the Sleep Disturbance Scale for Children (SDSC), OSA-18, and Paediatric Daytime Sleepiness Scale (PDSS). Mood and depressive symptoms were assessed via QOL-PCD and Children’s Depressive Inventory (CDI) as age-appropriate. Pulmonary function testing was performed via spirometry and Multiple Breath Washout. Patients underwent an ENT assessment. All children completed one night of polysomnography including transcutaneous CO2 and video monitoring. Progress to date: Twenty participants (45% female) have been recruited with a mean age of 8.5 years. Mean (±SD) FEV1 is 76.5±22.9%. 73% of children assessed have chronic rhinosinusitis. Clinically significant scores for SDSC were observed in 79% of patients and in 30% of patients for OSA-18. 38% of children reported clinically significant scores for PDSS. To date, 7 children have completed polysomnography. Intended outcome and impact: This is the first study to characterise sleep quality and the impact of sleep disturbance in Australian children with PCD. We aim to identify clinical markers of poor sleep quality to better inform the development of a sleep screening program for use in paediatric PCD clinics.

scholarly journals Interstitial lung disease in systemic sclerosis

2016 ◽  
Vol 67 (4) ◽  
Author(s):  
E.A. Renzoni
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Fibrosis ◽  
Immunosuppressive Agents ◽  
Significant Proportion ◽  
Clinical Markers ◽  
Significant Toxicity ◽  
Clinically Significant

Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis of the skin and internal organs, autoimmune abnormalities and widespread vasculopathy. A degree of interstitial lung involvement is present in the majority of patients, although clinically significant lung fibrosis is present in approximately a third. Autoantibodies are significant clinical markers; anti-topoisomerase is tightly linked to lung fibrosis, whereas anti-centromere antibodies are protective. Further evaluation of markers of progression of lung fibrosis, such as markers of epithelial permeability, will be crucial in clinical management. The clinical course of SSc-associated interstitial lung disease is highly variable, with stability observed in a significant proportion of patients. Therefore, the decision of whether to treat is a challenging one, and should be based on evaluation of disease severity (on the basis of CT extent and lung function) and longitudinal disease behaviour. Two recently published placebo controlled randomized trials have shown a significant, if small, effect of cyclophosphamide on preventing FVC decline. However, because of the significant toxicity of cyclophosphamide, the assessment of alternative, less toxic, immunosuppressive agents for the long term management of SSc-associated interstitial lung disease is needed.

Sign in / Sign up

Export Citation Format

Share Document